« Back to Stories Featured Science

WID Frontier Fellows Earn Spot in Popular Science #CrowdGrant Challenge [VIDEO]

A WID Frontier Fellows group has been selected by Popular Science magazine's #CrowdGrant Challenge.

AnaElise Beckman

AnaElise Beckman

A WID Frontier Fellows group is one of 24 selected by Popular Science magazine’s #CrowdGrant Challenge. The challenge highlights the “biggest, boldest science and technology project ideas,” encouraging public support to help make them happen. (Support this project).

The team includes undergraduate students AnaElise BeckmanMichael Zaiken and Alexandra Cohn.

The goal of the Biobulb is to create an ecosystem in a jar. The ecosystem will consist of several different microbes, each of which plays a role in nutrient recycling and population control. The result is a closed ecosystem that will sustain itself with the addition of light. The system will support a population of genetically engineered E. coli. These bacteria will be genetically modified for bioluminescence. The result, the student group says, will be a stable, closed, microbial ecosystem that glows in the dark.

Michael Zaiken

Michael Zaiken

Fellows plan on experimenting with different bioluminescence proteins to determine which species’ native genes produce the best glow in E. coli. They also plan to experiment with techniques to combat mutation as well as examine different colored light emission and triggers for the activation of the glowing bacteria.

Alexandra Cohn

Alexandra Cohn

Visit the group’s RocketHub page to learn more and support the project.

Related

WID’s first Frontier Fellows cohort merges science, abstraction, education

Frontier Fellows’ ‘Hanbot’ sketches images and data (video)


Press Contact:

WID Media
608-316-4325

More articles in Featured Science:

You may also like … Algorithms that improve drug discovery

WID researchers Stephen Wright and Robert Nowak are part of a UW2020: WARF Discovery Initiative project to create machine learning tools that dramatically reduce the time and cost associated with screening compounds for therapeutic relevance.